Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
J Med Chem. 2023 Feb 23;66(4):2589-2607. doi: 10.1021/acs.jmedchem.2c01535. Epub 2023 Feb 1.
Inflammasomes are innate immune signaling platforms that trigger pyroptotic cell death. NLRP1 and CARD8 are related human inflammasomes that detect similar danger signals, but NLRP1 has a higher activation threshold and triggers a more inflammatory form of pyroptosis. Both sense the accumulation of intracellular peptides with Xaa-Pro N-termini, but Xaa-Pro peptides on their own without a second danger signal only activate the CARD8 inflammasome. We recently reported that a dual inhibitor of the Xaa-Pro-cleaving M24B aminopeptidases PEPD and XPNPEP1 called CQ31 selectively activates the CARD8 inflammasome by inducing the build-up of Xaa-Pro peptides. Here, we performed structure-activity relationship studies on CQ31 to develop the optimized dual PEPD/XPNPEP1 inhibitor CQ80 that more effectively induces CARD8 inflammasome activation. We anticipate that CQ80 will become a valuable tool to study the basic biology and therapeutic potential of selective CARD8 inflammasome activation.
炎症小体是先天免疫信号平台,可引发细胞焦亡。NLRP1 和 CARD8 是相关的人类炎症小体,可检测相似的危险信号,但 NLRP1 的激活阈值较高,引发更具炎症性的细胞焦亡形式。两者均能感知具有 Xaa-Pro N-末端的细胞内肽的积累,但单独的 Xaa-Pro 肽在没有第二个危险信号的情况下仅激活 CARD8 炎症小体。我们最近报道,一种名为 CQ31 的 Xaa-Pro 切割 M24B 氨肽酶 PEPD 和 XPNPEP1 的双重抑制剂通过诱导 Xaa-Pro 肽的积累选择性激活 CARD8 炎症小体。在这里,我们对 CQ31 进行了结构-活性关系研究,开发了更有效地诱导 CARD8 炎症小体激活的优化双重 PEPD/XPNPEP1 抑制剂 CQ80。我们预计 CQ80 将成为研究选择性 CARD8 炎症小体激活的基础生物学和治疗潜力的有价值工具。